Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q2 FY23 results · Jul–Sep 2022
Marksans Pharma reported revenue from operations of ₹452.56 crore (up 25.3% from Q2 FY22) and net profit of ₹60.12 crore (up 29.9% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 452.56 | 361.20 | +25.3% | 433.77 | +4.3% |
| Other income | 14.15 | 8.57 | +65.2% | 16.50 | −14.2% |
| Total income | 466.72 | 369.77 | +26.2% | 450.27 | +3.7% |
| Profit before tax | 77.83 | 59.78 | +30.2% | 76.44 | +1.8% |
| Net profit for the period | 60.12 | 46.29 | +29.9% | 60.18 | −0.1% |
| Attributable to shareholders of the company | 61.25 | — | — | 59.72 | +2.6% |
| EPS, basic (₹) | 1.52 | 1.11 | +36.9% | 1.46 | +4.1% |
| Net margin (%) | 13.3 | 12.8 | 13.9 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 170.26 | 168.85 | +0.8% | 159.15 | +7.0% |
| Other income | 21.03 | 8.60 | +144.6% | 19.43 | +8.2% |
| Total income | 191.29 | 177.45 | +7.8% | 178.58 | +7.1% |
| Profit before tax | 48.98 | 37.02 | +32.3% | 25.70 | +90.6% |
| Net profit for the period | 40.23 | 27.60 | +45.8% | 19.21 | +109.5% |
| EPS, basic (₹) | 1.00 | 0.67 | +49.3% | 0.47 | +112.8% |
| Net margin (%) | 23.6 | 16.3 | 12.1 |
Consolidated
- Filed with BSE
- 16 Nov 2022, 18:06 IST
- Board meeting
- 14 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 16 Nov 2022, 18:06 IST
- Board meeting
- 14 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE